Judicial Review - judgement expected at 3pm

RNS Number : 1740C
Abingdon Health PLC
07 October 2022
 

 

Abingdon Health plc

("Abingdon Health" or "the Company")

 

Judicial Review - judgement expected at 3pm

 

York, U.K. 7 October 2022:  Abingdon Health plc (AIM: ABDX), a leading international developer and manufacturer of high quality and effective rapid tests, notes that the judgement in relation to the Judicial Review proceedings initiated by the Good Law Project Limited ("GLP") against the Department of Health and Social Care ("DHSC") is now expected to be handed down at 3pm today. Abingdon Health is an interested party in the case.

 

Details are provided in section 17.4 of this link:

https://www.gov.uk/government/publications/business-and-property-courts-rolls-building-cause-list/business-and-property-courts-of-england-and-wales-cause-list#technology-and-construction-court-kings-bench-division

 

A further announcement will be made once the outcome of the Judicial Review is known.

 

 

Enquiries

 

Abingdon Health plc

www.abingdonhealth.com/investors/

Chris Yates, Chief Executive Officer

Via Walbrook PR

Melanie Ross , Chief Financial Officer

 

Chris Hand, Non-Executive Chairman

 

 

 

Singer Capital Markets (Sole Broker and Nominated Adviser)

Tel: +44 (0)20 7496 3000

Peter Steel, Alex Bond (Corporate Finance)

 

Tom Salvesen (Corporate Broking)

 


 

Walbrook PR Limited

Tel: +44 (0)20 7933 8780 or abingdon@walbrookpr.com

Paul McManus / Phillip Marriage

Alice Woodings

Mob: +44 (0)7980 541 893 / +44 (0)7867 984 082

+44 (0)7407 804 654

 

 

About Abingdon Health plc

 

Abingdon Health is a world leading  developer and manufacturer of high-quality lateral flow rapid tests  across all industry sectors, including healthcare and COVID-19. Abingdon is the partner of choice for a growing global customer base and takes projects from initial concept through to routine and large-scale manufacturing and has also developed and marketed its own labelled tests.

 

The Company offers product development, regulatory support, technology transfer and manufacturing services for customers looking to develop new assays or transfer existing laboratory-based assays to a lateral flow format. Abingdon Health aims to support the increase in need for rapid results across many industries and locations and produces lateral flow tests in areas such as infectious disease, clinical testing including companion diagnostics, animal health and environmental testing. Faster access to results allows for rapid decision making, targeted intervention and can support better outcomes. This ability has a significant role to play in improving life across the world. To support this aim Abingdon Health has also developed AppDx®, a customisable image capturing technology that transforms a smartphone into a self-sufficient, standalone lateral-flow reader.

 

Founded in 2008, Abingdon Health is headquartered in York, England.

 

For more information visit:  www.abingdonhealth.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCBKOBNCBDKNKK
UK 100

Latest directors dealings